相关实验视频

Updated: Jul 19, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

在多发性骨髓瘤中使用CAR T细胞疗法,我们现在在哪里,我们正朝着什么方向发展?

Luise Fischer¹, Nora Grieb^1,2, Uwe Platzbecker¹

¹Department of Hematology, Cellular Therapy, Hemostaseology and Infectiology, University Hospital of Leipzig, Leipzig, Germany.

European journal of haematology

|August 7, 2023

概括

化学抗原受体 (CAR) T细胞疗法改变了复发性和耐火性多发性骨髓瘤的治疗方法. 本审查涵盖已批准的CAR T细胞产品,它们的最佳使用,以及多发性骨髓瘤的未来发展.

科学领域:

血液学血液学血液学
免疫治疗是一种免疫疗法.
在瘤学瘤学.

背景情况:

化学抗原受体 (CAR) T细胞代表了治疗复发性和耐火性多发性髓瘤 (RRMM) 的重大进展.
两种CAR T细胞产品已被批准用于患有三级耐火性疾病的患者,这些患者的缓解率很高.
最近的III期试验探索了CAR T细胞疗法在多发性骨髓瘤的早期治疗线.

研究的目的:

审查关于多发性骨髓瘤批准的CAR T细胞疗法的当前数据.
确定和讨论多发性骨髓瘤中CAR T细胞治疗的未满足的临床需求.
探索旨在优化多发性骨髓瘤中CAR T细胞使用的持续发展.

主要方法:

对已批准的CAR T细胞产品 (idecabtagene vicleucel和ciltacabtagene autoleucel) 发表的数据的审查.
在早期的治疗线路中分析了初始的III期试验.
对治疗多发性骨髓瘤的CAR T细胞疗法的临床不确定性和未来方向的讨论.

主要成果:

经批准的CAR T细胞疗法在RRMM中实现了深度和持久的缓解.
证据表明,在早期的疗法中有效,尽管正在研究最佳测序.
取得了显著的进展,但在最大限度地提高CAR T细胞疗法的影响方面仍然存在挑战.

结论:

汽车T细胞疗法已经彻底改变了RRMM治疗,为患者提供了新的希望.
需要进一步的研究来解决最佳使用,患者选择和可访问性问题.
目前正在进行的发展有望增强CAR T细胞治疗在治疗多发性骨髓瘤中的作用.

关键词:

在CAR T细胞中,在CRS中,您可以使用CRS.在ICANS中,我们可以看到ICANS.这样一来,Ciltacabtagene的自动解读就变成了Ciltacabtagene.这是一个很棒的项目. idecabtagene vicleucelelel vicleucel.多发性骨髓瘤是多发性骨髓瘤的一种.耐火材料耐火材料耐火材料这是一个复发的复发.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...